News7 min readDecember 23, 2025

Wegovy Pill: FDA Approves First Oral GLP-1 for Weight Loss

FDA approves once-daily Wegovy pill, the first oral GLP-1 medication for weight loss. What you need to know about this new option.

By Med Consumer Watch Team

On December 22, 2025, the FDA approved once-daily Wegovy pill—the first oral GLP-1 medication specifically approved for weight management in the US. This marks a significant shift in obesity treatment, offering an alternative to weekly injections.

What Is Wegovy Pill?

Wegovy pill is an oral formulation of semaglutide, the same active ingredient in injectable Wegovy and Ozempic. Key details: • Once-daily pill taken in the morning • Maximum dose: 25mg daily • First and only FDA-approved oral GLP-1 for obesity • Same medication as injectable Wegovy, different delivery method • Also approved to reduce cardiovascular risk in adults with obesity and heart disease

Clinical Trial Results

The OASIS 4 trial demonstrated significant efficacy: • Average weight loss: 14% over 64 weeks • Placebo group: 2% weight loss • With full adherence: 16.6% mean weight loss • Comparable to injectable formulations at lower doses These results position the oral version as a legitimate alternative to injections for many patients.

The 14% average weight loss is measured at the maximum 25mg dose after the full titration period.

How to Take Wegovy Pill

Specific administration requirements: • Take on empty stomach first thing in the morning • With no more than 4 oz of plain water • Wait at least 30 minutes before eating, drinking, or taking other medications • Take at approximately the same time daily These requirements are crucial for proper absorption.

Not following the dosing instructions can significantly reduce the medication's effectiveness.

Pricing and Availability

Wegovy pill will be available starting early January 2026: • Starting dose (1.5mg): $149 per month • Available at pharmacies and select telehealth providers • Higher doses may have different pricing • Insurance coverage details still emerging The starting price point is significantly lower than injectable Wegovy without insurance. For those seeking injectable semaglutide now, our top-rated provider CoreAge Rx (9.9/10) offers compounded semaglutide with comprehensive medical oversight, personalized treatment plans, and ongoing physician support. See our full CoreAge Rx review or visit CoreAge Rx.

Oral vs. Injectable Wegovy

Comparing the two formulations: Injectable Wegovy: • Once-weekly injection • Maximum dose: 2.4mg weekly • Established track record • Average weight loss: 15-17% Oral Wegovy: • Once-daily pill • Maximum dose: 25mg daily • Convenient for needle-phobic patients • Average weight loss: 14-16.6% • Strict timing requirements

Who Might Prefer the Pill?

The oral formulation may appeal to those who: • Have needle phobia or injection anxiety • Prefer daily medication over weekly injections • Want more control over dosing schedule • Travel frequently and prefer pills • Have difficulty with injection sites However, those who struggle with daily medication compliance may prefer weekly injections. If you're considering semaglutide treatment now and don't want to wait for the pill version, we recommend CoreAge Rx—our highest-rated provider (9.9/10) offering injectable compounded semaglutide with exceptional medical support and transparent pricing.

Cardiovascular Benefits

The approval includes an additional indication: The Wegovy pill is also approved to reduce the risk of major cardiovascular events—including death, heart attack, and stroke—in adults with obesity and established cardiovascular disease. This dual indication makes it particularly valuable for patients with both obesity and heart conditions.

Competition on the Horizon

Novo Nordisk won't have the oral GLP-1 obesity market to itself for long: • Eli Lilly's orforglipron expected FDA approval by summer 2026 • Different molecule, potentially different side effect profile • May offer additional options for patients The expanding oral GLP-1 market signals increasing access to obesity treatment.

The Bottom Line

The FDA approval of Wegovy pill represents a meaningful expansion in obesity treatment options. With 14% average weight loss and the convenience of oral dosing, it offers a compelling alternative to injections for many patients. The $149 starting price and early 2026 availability make it accessible, though full insurance coverage remains to be determined. For patients who've avoided GLP-1 medications due to injection concerns, this approval opens new possibilities. If you're ready to start GLP-1 treatment now, our top recommendation is CoreAge Rx (rated 9.9/10), which offers compounded semaglutide with comprehensive medical oversight. Read our full CoreAge Rx review to learn why they're our highest-rated provider.

Sources & References

FDA - Wegovy Pill Approval
Novo Nordisk Press Release
OASIS 4 Clinical Trial

Medical Disclaimer

This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.

CoreAge Rx Semaglutide Review

Our top-rated provider (9.9/10) for injectable semaglutide.

Wegovy Pill: In-Depth Review

Comprehensive analysis of the new oral semaglutide formulation.

Effects of Rybelsus for Weight Loss

How the diabetes oral semaglutide compares for weight loss.

Back to All Articles

Enter to Win a $1,788 CoreAge Rx Gift Card

Enter for a chance to use it toward eligible CoreAge Rx products and services.

The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.